Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.

Department of Oncology, The Finsen Centre, Copenhagen University Hospital Rigshospitalet, Denmark.
Acta oncologica (Stockholm, Sweden) (Impact Factor: 2.27). 02/2012; 51(2):234-42. DOI: 10.3109/0284186X.2011.619568
Source: PubMed

ABSTRACT Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
In this multi-center phase II trial patients with chemoresistant, metastatic upper gastrointestinal cancer were treated with erlotinib (150 mg daily) and bevacizumab (10 mg/kg every two weeks). Primary endpoint was overall response rate (ORR). Secondary endpoints were progression free survival (PFS), overall survival (OS), toxicity and biomarker correlates. Plasma samples were analysed for EGFR and angiogenesis related markers using quantitative immunoassays.
One hundred and two patients were enrolled in the trial between June 2006 and October 2007. The most common toxicities were skin reaction, diarrhoea, and fatigue. ORR was 6%, median PFS was 2.2 months, and OS 4.3 months. Low concentration of urokinase plasminogen activator receptor (uPAR) domain I was correlated to longer PFS and OS.
The combination of erlotinib and bevacizumab is well tolerated, however, with low clinical activity in patients with chemoresistant UGI cancer. Some patients do benefit from the therapy, and uPAR forms are potential biomarkers in these patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background High levels of intact and cleaved forms of the urokinase-type plasminogen activator receptor (uPAR) in both tissue and blood are associated with poor survival in several cancer diseases. The prognostic significance of uPAR in cholangiocarcinoma is unknown. The aims of this study were to determine if pre-treatment serum levels of uPAR forms and a decrease in levels during chemotherapy are predictive of survival in patients with inoperable cholangiocarcinoma. Design and Methods Patients with inoperable cholangiocarcinoma were consecutively included in the training set (n = 108). A test set included patients from a different hospital using similar treatment guidelines (n = 60). Serum levels of the different uPAR forms were determined using time-resolved fluorescence immunoassays (TR-FIA). The Cox proportional hazards model was used for the uni- and multivariate survival analyses. Results Baseline level of uPAR(I-III) + uPAR(II-III) was an independent predictor of survival (HR = 2.08 95% CI:1.46-2.97, p < 0.0001). Applying the linear predictor from the training set to the test set, it was validated that uPAR(I-III) + uPAR(II-III) predicted overall survival (p = 0.049). A high level of uPAR(I-III) + uPAR(II-III) after 2 cycles of chemotherapy was associated with poor survival (HR = 1.79, 95% CI:1.08-2.97, p = 0.023, n = 57).This predictor, however, was not significant in the test set (p = 0.21, 26 events in 27 patients). Conclusion The baseline level of uPAR(I-III) + uPAR(II-III) is a predictor of survival in inoperable cholangiocarcinoma patients.
    Clinical biochemistry 01/2014; · 2.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The plethora of novel molecular-targeted agents (MTAs) has provided an opportunity to selectively target pathways involved in carcinogenesis and tumour progression. Combination strategies of MTAs are being used to inhibit multiple aberrant pathways in the hope of optimizing antitumour efficacy and to prevent development of resistance. While the selection of specific agents in a given combination has been based on biological considerations (including the role of the putative targets in cancer) and the interactions of the agents used in combination, there has been little exploration of the possible enhanced toxicity of combinations resulting from alterations in multiple signalling pathways in normal cell biology. Owing to the complex networks and crosstalk that govern normal and tumour cell proliferation, inhibiting multiple pathways with MTA combinations can result in unpredictable disturbances in normal physiology. This Review focuses on the main toxicities and the lack of tolerability of some common MTA combinations, particularly where evidence of enhanced toxicity compared to either agent alone is documented or there is development of unexpected toxicity. Toxicities caused by MTA combinations highlight the need to introduce new preclinical testing paradigms early in the drug development process for the assessment of chronic toxicities resulting from such combinations.
    Nature Reviews Clinical Oncology 01/2013; · 15.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biliary tract cancer is a rare malignant tumor. Accordingly, to perform prospective and randomized trials is difficult and the knowledge of its natural history and optimal management remains limited. Chemotherapy is commonly used to improve the outcome and to delay tumor progression in advanced disease. Only recently, cisplatin-gemcitabine combination was identified as the new standard first-line therapy. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment maintain a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified yet. Experiences of salvage therapy in advanced biliary tract cancer are sparse and yielded disappointing results. Well designed multi-institutional randomized trials are warranted to clarify the role and the activity of a second-line therapy.
    Critical reviews in oncology/hematology 06/2013; · 5.27 Impact Factor

Full-text (2 Sources)

Available from
Aug 4, 2014